ecancermedicalscience

Short Communication

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

28 Feb 2017
Herman Andrés Perroud, O Graciela Scharovsky, Viviana Rosa Rozados, Carlos María Alasino

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Related Articles

Agnes Chipo Tererai, Margaret Borok, Zvavahera Mike Chirenje, Liz Gwyther, Lindsay Farrant, Ntokozo Ndlovu, Simbarashe Rusakaniko
Gustavo Santos Paiva Laender Moura, Laura Gonzaga de Carvalho Bonifácio, Fernando Pedreschi Bernardes, Livia Regina Gonçalves e Silva, Vivian Marques Miguel Suen, Maria Izaura Sedoguti Scudeler Agnollitto, Rosana Aparecida Spadoti Dantas, Nereida Kilza da Costa Lima, Mevhibe Banu Hocaoglu
Liudmila Castelo David, Teresa Mota Garcia, Isaulina Barreto, Esperança Carvalho, Laurinda Barreto, Clara Aleydis, Laurinda Coelho, Lúcio Lara Santos
Tsion Zebdiwos Chema, Edom Seife Woldetsadik, Girum Tessema Zingeta, Hawi Furgassa Bedada, Mohammed Ibrahim Adem, Jilcha Diribi Feyisa, Winini Belay, Mushonga Melinda, K S Han Kathy, Rebecca Wong, Munir Awol, Bargude Balta